Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334775 | 0.86 | ALDH1A1 (0.43) | OPRL1OPRM1OPRK1ALDH1A1MMP1 | |
| Hydrochloric Acid SCHEMBL6329702 | 0.85 | ALDH1A1 (0.42) | OPRL1OPRM1OPRK1ALDH1A1MMP1 | |
| SCHEMBL28324849 | 0.82 | KDM1A (0.44) | OPRL1OPRM1OPRK1ALDH1A1VNN1 | |
| SCHEMBL28320698 | 0.81 | SSTR4 (0.46) | ALDH1A1MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL23023788 | 0.75 | OPRM1 (0.47) | OPRL1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL12862918 | 0.75 | TACR1 (0.46) | OPRL1OPRM1OPRK1ALDH1A1MEN1 | |
| SCHEMBL11674919 | 0.70 | TDP1 (0.52) | ALDH1A1MEN1KMT2AMAPTRXFP1 | |
| SCHEMBL8012043 | 0.70 | TDP1 (0.52) | ALDH1A1MEN1KMT2AMAPTRXFP1 | |
| SCHEMBL8146159 | 0.69 | OPRM1 (0.42) | OPRL1OPRM1OPRK1ALDH1A1POLB | |
| SCHEMBL3402516 | 0.69 | OPRM1 (0.52) | OPRL1OPRM1OPRK1ALDH1A1VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS SA (ES) | 2018-10-04 | — | — | US | claimed |
| EP-2361242-B1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS SA (ES) | 2018-08-01 | — | — | EP | claimed |
| US-9186337-B2 | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae | ORYZON GENOMICS S.A. (ES) | 2015-11-17 | — | — | US | claimed |
| US-8524717-B2 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2013-09-03 | — | — | US | claimed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | claimed |
| EP-2361242-A1 | OXIDASE INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2011-08-31 | — | — | EP | claimed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | claimed |
| EP-2177502-A1 | Compounds and their use | Oryzon Genomics, S.A. (ES) | 2010-04-21 | — | — | EP | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| EP-3013424-B1 | LSD INHIBITORS FOR MODULATING CANCER STEM CELLS | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2024-09-25 | — | — | EP | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| WO-2011106573-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106106-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106574-A2 | INHIBITORS FOR ANTIVIRAL USE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| EP-2361242-A1 | OXIDASE INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177502-A1 | Compounds and their use | Oryzon Genomics, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | OPRL1 2150/4885OPRM1 4013/4885OPRK1 3065/4885 |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | KDM1B, EZH2, DOT1L | OPRL1 3935/4885OPRM1 3970/4885OPRK1 4007/4885 |
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | OPRL1 990/4885OPRM1 678/4885OPRK1 1111/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | OPRL1 661/4885OPRM1 721/4885OPRK1 887/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | OPRL1 2150/4885OPRM1 4013/4885OPRK1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.